Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in Newly Diagnosed CML
NCT02353728Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Jan 2015
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nilotinib in chronic myeloid leukemia (CML), sponsored by Weill Cornell Medicine. Primary endpoint: Percentage of Leukemic Stem Cells Present in Bone Marrow Aspirate Samples at 12 months. Started Jan 2015; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02353728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02353728.